Navigation Links
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Date:6/12/2008

PARIS, June 13 /PRNewswire-FirstCall/ -- Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years of treatment among 74 percent of patients tested. AS is a type of arthritis that primarily causes inflammation of the spine and the spinal joints. These data were presented at the European League Against Rheumatism (EULAR) annual meeting in Paris.

"There is no cure for ankylosing spondylitis and the goal of therapy is to relieve back and joint pain," said Desiree van der Heijde, M.D., co-lead investigator of ATLAS and Professor of Rheumatology at Leiden University Medical Center, The Netherlands. "Even partial remission of AS can have a considerable positive impact on a patient's symptoms. These data are reassuring for patients because they demonstrate that adalimumab can be an effective treatment for ankylosing spondylitis."

Three-Year ATLAS Data Summary

ATLAS was a randomized, placebo-controlled, double-blind, Phase III study conducted in the U.S. and Europe. The study involved 315 patients with active AS who had an inadequate response to at least one non-steroidal anti-inflammatory drug (NSAID) or disease modifying anti-rheumatic drug (DMARD). Patients received HUMIRA 40mg subcutaneously or placebo every other week (EOW). Results at 12 and 24 weeks showed HUMIRA patients experienced a statistically significant reduction in signs and symptoms according to the Assessment in SpondyloArthritis International Society (ASAS) measure, or ASAS20 compared to placebo. ASAS20 represents at least a 20 percent improvement in at least three of the four assessments to measure patient improvement and response to therapy. At 24 weeks, all patients were switched to an open-label HUMIRA 40mg EOW dose trial for an additional 236 weeks. Impr
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
4. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
5. The CoverMe Foundation Offers Free, Step-By-Step Assistance to Connect Uninsured with Free or Reduced-Cost Health Care
6. Family history of colorectal cancer linked with reduced risk of cancer recurrence
7. Hot Flashes Reduced by Neck Injection
8. Ibuprofen Linked to Reduced Alzheimers Risk
9. Reduced emergency room visits for elderly patients attributed to virtual health care team approach
10. Autistic mannerisms reduced by sensory treatment
11. Competing San Francisco Bay Area Hospitals Demonstrate That Collaborative Efforts Contribute to Reduced Hospital Errors and Saved Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
(Date:9/17/2014)... Washington, DC (PRWEB) September 17, 2014 ... family history. Along with regular screening and examination, a ... In this episode of Epicure with the Chef ... GWMFA Urologist Dr. Paul Rusilko to prepare a delicious ... in our western diets that influence risk of prostate ...
(Date:9/17/2014)... 2014 “North America Gynecological Devices ... on the North America Gynecological Devices market. The ... volume (in units) and average prices (in US ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) ... , Endometrial Ablation Devices (Thermal Balloon, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Stand Up ... and music, returns to the Theater at Madison Square ... the Bob Woodruff Foundation (BWF) and New York Comedy ... returning service members, veterans and their families. , ... John Mulaney, John Oliver, Bruce Springsteen, Brian Williams and ...
(Date:9/17/2014)... Alpharetta, GA (PRWEB) September 17, 2014 ... Background Screeners (NAPBS®) Background Screening Credentialing Council ... demonstrated compliance with the Background Screening Agency ... formally recognized as BSCC-Accredited. , S2Verify, ... , Each year, U.S. employers, organizations and ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 2Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 3Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 5Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 2Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 3
... , , COLCHESTER, ... College of Pharmacy and Health Sciences opened its Vermont Satellite Campus ... in scenic Colchester, Vermont, is home to the only pharmacy program ... campus offers a four year program culminating in a Doctor of ...
... ... Eye Institute of Utah – a prominent Salt Lake City, Utah ... a national award recognizing the quality of its work. Known as one of ... Springs, Wyoming location has been named by the U.S. Commerce Association as one ...
... U.S. Commerce ... living with Diabetes. , ... Raton, FL (PRWEB) August 31, 2009 -- Leading provider of diabetes medical supplies, American Diabetes ... Medical Supplies category by the U.S. Commerce Association (USCA). The company is aiding those ...
... ... solution to address current challenges in public health reporting and to improve the early detection, ... , ... 2009 -- Orion Health, Inc. and Cisco today announced the Rhapsody® ...
... , , MAASTRICHT, ... VAR ) is introducing the world,s first low-energy radiotherapy ... clinics. Varian,s UNIQUE(TM) radiotherapy system is expected to make advanced ... around the world. , , "This package ...
... , , NUTLEY, N.J., ... that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) ... kidney and heart transplant patients (4 months to 16 years of ... also approved a new pediatric oral solution formulation for Valcyte, which ...
Cached Medicine News:Health News:Albany College of Pharmacy and Health Sciences Opens Vermont Satellite Campus 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 3Health News:Provider of Diabetes Medical Supplies Receives 2009 Best of Boca Raton Award 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 3Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 4Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 2Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 2Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 4
(Date:9/17/2014)... , Sept. 17, 2014  Trovagene, Inc., (NASDAQ: ... today that Alberto Bardelli , Ph.D., has joined ... the first to identify mutations in the kinase genes ... Currently, he is at the Department of Oncology, Torino ... Italy . "Alberto,s work ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... , Sept. 17, 2014 Research ... "Global Breast Cancer Market 2014-2018" report to ... by the uncontrolled growth of cancerous cells in the ... however, male breast cancer is rare. Histologically, breast cancer ... cancer and other undifferentiated carcinoma. Ductal carcinoma is the ...
Breaking Medicine Technology:Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3
... (OTC Bulletin Board: CGNH ) announced today that ... 2 Class B common stockholders a "Stockholder Questionnaire," which the ... count of the Company,s shares currently held in "street ... If you have not received the Stockholder Questionnaires via ...
... VILLAGE, Nev., March 8, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... rate for its 2.00% Convertible Senior Notes due February 15, 2012 ... 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection ... to all stockholders who own shares of PDL on March 8, ...
Cached Medicine Technology:CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires 2PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015 2
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: